In 90 consecutive patients with multiple myeloma, we investigated the feasibility of administering a tandem high-dose therapy regimen, using whole blood for rescue after the first and leucapheresis harvested between the two high doses, for rescue after the second high dose. After 5 days of G-CSF 1 litre of whole blood (WB) was obtained, left undisturbed at 4؇C and reinfused 24 h after HDM (140 mg/m 2 ). Patients not in progression after 3-6 months were again mobilised, leucapheresed and treated with busulphan 16 mg/kg and cyclophosphamide 120 mg/kg (Bu/Cy) and reinfusion. In 90 patients, WB contained a mean (range) of 0.57 (0.02-3.22) ؋ 10 6 /kg CD34 ؉ cells. Recovery after HDM was in 13 days for granulocytes and in 18 days for platelets, with 11 patients not recovering within 3 months. There were three toxic deaths. Sixty-six patients qualified for harvesting after HDM. In the first 11, marrow was harvested. The subsequent 55 patients were mobilised and in 45 the preset minimum of 1.5 ؋ 10 6 CD34 ؉ cells was obtained. Forty-nine patients actually received Bu/Cy. Recovery after Bu/Cy and marrow reinfusion was in 35 days for granulocytes and 20 days for platelets, with two of five patients not recovering after 3 months. After Bu/Cy and leucapheresis reinfusion, recovery was in 17 days for granulocytes and in 34 days for platelets. Nine patients did not recover within 3 months. There were four toxic deaths. The median overall survival from diagnosis for patients receiving HDM was 49 months and for patients also receiving Bu/Cy, 84 months. We conclude that WB rescue after HDM followed by leucapheresis and a second transplant is feasible in the majority of patients. Better mobilisation techniques are required to increase the number of patients who can receive the second transplant. Bone Marrow Transplantation (2001) Multiple myeloma is uniformly lethal with a median survival of less than 3 years in most studies. In a series of comparative studies, combination chemotherapy did not result in a better outcome as compared to the classic melphalan-prednisone combination, already in use for 30 years.
Multiple myeloma is uniformly lethal with a median survival of less than 3 years in most studies. In a series of comparative studies, combination chemotherapy did not result in a better outcome as compared to the classic melphalan-prednisone combination, already in use for 30 years.
1,2 High-dose melphalan (HDM), with or without stem cell rescue, has been extensively explored in multiple myeloma. High rates of response and even complete remissions have been reported, but in general responses are not long lasting. 3, 4 In the one comparative study in which high-dose chemoradiotherapy with autologous stem cell transplantation was compared with conventional chemotherapy, Attal and co-workers showed the high-dose therapy to be superior with respect to event-free and overall survival. 5 However, the survival curves did not show a plateau and cure is not likely to occur very frequently. In order to improve outcome, some groups have explored tandem transplantations. 6, 7 These protocols have in common that haematopoietic stem cells are harvested prior to the use of high-dose melphalan, because melphalan is toxic for the stem cell compartment and is supposed to considerably hinder stem cell collection. 8 The harvest is usually performed after a few cycles of chemotherapy, commonly VAD or VAD-like protocols, resulting in stem cell grafts which contain a considerable tumour load. 9, 10 One approach to increase the efficacy of the second transplant would be to harvest stem cells after rather than before the first highdose therapy. However, this would imply two leucapheresis sessions, one for the first and another for the second transplant. To make this approach feasible, we used as the first high-dose therapy, high-dose melphalan followed by G-CSF-primed whole blood rescue as described by us before. 11 After this treatment, stem cells were harvested from the bone marrow or peripheral blood in eligible patients and a second transplantation, using a conditioning regimen consisting of busulphan-cyclophosphamide, was performed.
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Patients and methods
All patients referred to our hospital who were less than 65 years of age with or without prior treatment for multiple myeloma were entered into the study. Criteria for exclusion were severely abnormal cardiac or pulmonary function, serum creatinin above 250 mol/l, serum bilirubin above 35 mol/l, ALAT and/or ASAT above four times normal, other severe non-haematological disease, or refusal to participate. Patients were required to have a WHO performance status of 0-2, but there were no requirements for response to prior treatment, if any.
Non-pre-treated, newly diagnosed patients received two to four cycles of VAD or VAMP (vincristine, adriamycin, dexamethasone or methylprednisolone) and proceeded to HDM, regardless of response. Pre-treated patients directly received HDM. HDM was given as described by us in detail before. 11 In short, G-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA), 10 g/kg, was given daily subcutaneously during 5 days, after which 1 litre of whole blood was obtained by venepuncture and stored unmanipulated at 4°C. Subsequently HDM, 140 mg/m 2 , was given intravenously in 10 min. After 24 h the 1 litre of G-CSF stimulated blood was reinfused. G-CSF was reinstituted after reinfusion at a dose of 5 g/kg daily until granulocytes were Ͼ0.5 ϫ 10 9 /l. About 3 to 6 months after HDM, the clinical response was determined. If no progression of disease was observed, peripheral blood counts were restored (platelets Ͼ100 ϫ 10 9 /l), bone marrow hypoplasia was regenerated, WHO status was 0-2 and if patients consented, stem cells were harvested. In the first 11 patients, bone marrow (BM) was harvested under general anaesthesia and cryopreserved using standard methods. 12, 13 In subsequent patients, peripheral blood stem cells (PBSC) were harvested by leucapheresis after administration of G-CSF, 10-12 g/kg subcutaneously, two times daily for at least 5 days. PBSC were cryopreserved using standard procedures. Subsequently, a second transplant was performed using busulphan 4 mg/kg orally for 4 days and cyclophosphamide 60 mg/kg intravenously for 2 days (Bu/Cy) as conditioning regimen. After 1 day of rest, stem cells were reinfused. 12, 13 During both HDM and Bu/Cy treatment, patients were given supportive care with prophylactic ciprofloxacin, fluconazole and intranasal amphotericin B. Intravenous antibiotics, antifungal agents and leucocyte-poor red cell concentrates were given if clinically indicated. Leucocyte poor platelet concentrates were given prophylactically when platelets were Ͻ10 ϫ 10 9 /l or if clinically indicated.
Response criteria and statistics
A complete remission (CR) was defined as a complete disappearance of monoclonal proteins on immunofixation, less than 5% plasma cells in the bone marrow and stable skeletal lesions. A partial remission (PR) was defined as Ͼ75% reduction in monoclonal proteins and improvement (IP) as a reduction between 50 and 75%. No response (NR) represented a reduction of less than 50%. Progression (Prog) was defined as an increase in monoclonal proteins of 20% or more or new skeletal lesions. Toxic death was defined as death within 3 months after transplantation.
Overall survival (OS) was calculated from the date of diagnosis and from the date of the first (HDM) transplantation, event-free survival (EFS) was only calculated from the date of HDM, both using the Kaplan-Meier method.
The logrank test was used to compare differences in survival between the patients with HDM only and the patients with HDM and Bu/Cy. Differences were considered statistically significant if P Ͻ0.05.
OS was defined as the time in months from the date of diagnosis or HDM until the date of death or at the time of evaluation. EFS was defined as the time in months from date of HDM until date of relapse, date of progression or date of death.
Results
Patient characteristics
In total, 90 consecutive patients were referred for high-dose therapy between July 1992 and December 1997. Their baseline characteristics are given in Table 1 . Forty-six patients were treated upfront and received two to four VAD or VAMP courses before the administration of HDM, with a median of 4 months (range 2-74). The other 44 patients were referred after a period of conventional chemotherapy, with a median of 17 months (range 4-129). The median time for all 90 patients from initial diagnosis until HDM was 6 months (range 2-129). Ten patients received melphalan and prednisone, one patient received only dexamethasone and the remaining 33 patients received a variety of chemotherapeutic regimens such as melphalan and prednisone-containing (29 patients) and/or cyclophosphamide, vincristine, prednisone (12 patients)-containing multidrug regimens. Most of these 33 patients (23) also received VAD or VAMP before the administration of HDM. Of the 90 patients, 28 patients were treated with limited radiotherapy. For an overview of the protocol see Figure 1 .
High-dose melphalan
After mobilisation by 5 days of G-CSF administration 1 litre of blood, containing a mean of 0.57 (median 0.44) ϫ 10 6 CD34 ϩ cells (range 0.02-3.22) per kilogram body weight, was harvested. Harvesting 1 litre of whole blood resulted in transient hypotension, responding to fluid replacement, in three patients.
Toxicity of HDM and whole blood rescue was quite mild. Mucositis WHO grade Ͼ2 was present in 21 patients. Of the 90 patients, 40 patients developed fever of unknown origin. A clinically or microbiologically documented infec- tion was observed in 26 patients, of whom six were WHO grade 3 and 4. Four developed septicaemia and two had pulmonary infections. Three patients died, one because of Aspergillus septicaemia and one because of septicaemia of unknown origin. One patient died, 12 weeks after HDM, with no obvious cause of death. All three patients were pretreated with at least four courses of M/P (Figure 1 ). Twenty-two out of 90 patients developed other toxicities with WHO grade 3, particularly vomiting (6), nausea (3), diarrhoea (3), dyspnea (2) and anaphylactic reactions (2) of which one was on platelet concentrates and one was on melphalan. One patient developed nausea WHO grade 4.
Haematological recovery was rather fast for granulocytes. The median time to reach 0.5 ϫ 10 9 /l of granulocytes was 13 days (range 10-33). One patient did not recover within 3 months. Platelet recovery was slower, with a median time of 18 days (range 9-91) to reach platelets Ͼ20
Bone Marrow Transplantation ϫ 10 9 /l. Eleven patients did not recover within 3 months. Of these 11 patients, five patients, inclusive of the three toxic deaths, had not recovered at the time of their death, and six patients did recover eventually (range 114-438 days after HDM). The content of CD34 ϩ cells in the whole blood graft of these 11 patients was a mean of 0.07 ϫ 10 6 /kg (median 0.06 (range 0.02-0.15)). Of the 11 patients with a slow platelet recovery, nine patients were pre-treated with melphalan or melphalan containing regimens for a median of 26 months (range 6-116), a 9 month difference from the value of the whole, pre-treated group of 44 patients.
Remission status was assessed 3 months after HDM. An increase in CR and PR was observed after HDM compared with the status before HDM. Of the 90 patients, 68 showed a response after HDM. Nineteen patients had a CR (21%), 27 patients had a PR (30%) and 22 patients showed an improvement (24%). The efficacy of HDM is given in Table 2 . 
Stem cell harvesting after HDM
Stem cell harvesting was attempted when at least 3 to 6 months had elapsed after HDM, and if peripheral blood cell counts were normalised. Furthermore, patients in progression and patients with a WHO performance status Ͼ2 were also excluded. Patients who were in retrospect in progression at the time of harvesting remained in the study. In 24 patients, no attempt to harvest stem cells was performed. Of these patients, 17 patients had a response (CR, PR or IP) after HDM. The reasons for not attempting to harvest stem cells in these 24 patients were thrombocytopenia (8), progression of disease within 5 months after HDM (4), refusal (4), a WHO performance status of 3 (3), early death (3), hypoplasia of the bone marrow (1) and not being insured (1) (Figure 1 ). In the first 11 patients bone marrow (BM) was harvested, in 55 patients peripheral blood stem cells (PBSC) were harvested using a median of four (range 2-13) leucapheresis procedures, each of about 10 litre of blood. For BM, a minimum of 2 ϫ 10 8 /kg nucleated cells and for PBSC a minimum of 1.5 x 10 6 /kg CD34 ϩ cells was required to classify as an adequate harvest. Such a number could not be reached in 10 of the 55 patients scheduled for PB harvesting. However, two of them were transplanted with a lower number of CD34 ϩ cells (1.40 and 1.46 ϫ 10 6 /kg) and one patient was transplanted with BM material harvested 5 years prior to transplant. The mean PBSC harvest was 2.14 (median 2.11) ϫ 10 6 CD34 ϩ cells per kilogram body weight (range 0.30-6.80).
Bu/Cy with BM/PBSC stem cell reinfusion
Of the 11 BM and 55 PBSC patients scheduled for Bu/Cy, 49 were actually transplanted. The most important reason for no transplantation was an inadequate harvest (7), of whom five patients had a CR, PR or IP. Other reasons were: thrombocytopenia (5), rapidly progressive disease between harvesting and planned date of Bu/Cy (3), refusal (1) and anti-coagulant therapy (1) (Figure 1) .
The toxicity of Bu/Cy was considerable. Mucositis requiring the administration of intravenous morphine for pain killing (WHO grade 3 and 4) was present in 17 patients. Fever of undetermined origin developed in 37 patients. Twenty patients had a clinically or microbiologically documented infection, of whom 12 patients had a WHO grade 3, including septicaemia (10), pulmonary infection (1) and skin infection (1). Other toxicities WHO grade у3 were nausea and vomiting (6), liver toxicity (5), haemorrhage (3), neurotoxicity (3), renal and bladder toxicity (2), dyspnea (2), cardiac dysrhythmias (1) and exanthema (1). Four patients died within 3 months after transplantation. One patient died of septic shock with multiorgan failure, one patient died with veno-occlusive disease of the liver and one patient died with no obvious cause of death. One patient died 11 weeks after Bu/Cy because of Staphylococcus aureus septicaemia and suspected venoocclusive disease of the liver (Figure 1) .
Haematological recovery was rather slow in the five patients transplanted with BM. The median time to reach granulocytes Ͼ0.5 ϫ 10 9 /l was 35 days (range 18-59) and the median time to reach platelets Ͼ20 ϫ 10 9 /l was 20.5 days (range 12-27) for three patients. One patient did reach this value after 21 months and one patient did not recover until his death. The other 44 patients were transplanted with peripheral blood stem cells. The median time to reach granulocytes Ͼ0.5 ϫ 10 9 /l was 17 days (range 13-46) and the median time to reach platelets Ͼ20 ϫ 10 9 /l was 34.0 days (range 0-96). Nine patients did not reach platelet recovery within 3 months. Seven patients did not recover at the time of their death, including the four patients who died within 3 months, one patient did recover after 15 months and one patient did not recover at the time of evaluation (2 years after HDM).
Three months after Bu/Cy the remission status of these double transplanted patients was assessed. A further increase in CR and PR and a decrease in Prog were observed compared with the status before Bu/Cy. The efficacy of Bu/Cy is given in Table 3 .
Event-free survival (EFS)
At the time of evaluation, 1 September 1999, the median EFS of all 90 patients as from the date of HDM was 23 months (range 1-84). For the 41 patients with only HDM and whole blood reinfusion the median EFS was 11 months (range 1-56) and for the 49 patients who also received Bu/Cy the median EFS was 32 months (range 6-84). The difference between only HDM and HDM and Bu/Cy was statistically significant (P Ͻ 0.0001) (Figure 2 ).
Overall survival (OS)
Overall survival of the whole group as from the date of diagnosis is shown in Figure 3a , and from the date of HDM in Figure 3b . Both were compared for the HDM group and HDM with the Bu/Cy group. At the time of evaluation the median OS of the 90 patients as from the date of diagnosis was 66 months (range 6-152). The survival for the double transplanted group was prolonged compared with the single transplanted group. Median OS for the HDM group was 49 months (range 6-152) and for the HDM and Bu/Cy group 84 months (range . The difference between these two groups is borderline statistically significant (P ϭ 0.0593).
As from the date of HDM, the median OS of all 90 patients was 38 months (range 1-84). For the 41 patients with only HDM the median OS was 26 months (range 1-929 Table 3 Results of treatment of the Bu/Cy transplanted patients Number  49  49  49  49  Complete remission  1  10  8  13  Partial remission  9  19  15  17  Improvement  14  12  14  12  No response  23  6  3  2  Progression  2  1  9  1  Toxic 83) and for the 49 patients who were double transplanted the median OS was 61 months (range 7-84). The difference between only HDM and double transplantation is statistically significant (P ϭ 0.0006) (Figure 3b ). At time of evaluation, 48 of 90 patients had died, 29 of 41 patients in the single transplanted group and 19 of 49 patients in the double transplanted group.
Before HDM After HDM Before Bu/Cy After Bu/Cy
Characteristics of patients reaching Bu/Cy transplantation
Patients reaching the second (Bu/Cy) stem cell transplantation were not older (mean 49.8 years vs 52.8 years) than those who failed to continue after HDM (only HDM). Initially, 61% of Bu/Cy receiving patients were in stage III, while 68% of the patients receiving only HDM were in stage III. However, of the patients receiving only HDM, 66% were pre-treated before entering the study, while in the Bu/Cy reaching patients, only 33% received other chemotherapy before entering the study. This represents a statistically significant difference (P Ͻ 0.01). As stated earlier, most of these pre-treated patients received melphalan-containing regimens.
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Discussion
In the past 20 years, the survival of patients with multiple myeloma has only marginally improved. High-dose chemo(radio)therapy followed by autologous stem cell transplantation is more effective than conventional chemotherapy in newly diagnosed patients but cure is seldom achieved. 5 In patients who have developed resistance to conventional therapy standard salvage regimens result only in short-term palliation, producing median survivals of less than 12 months. [14] [15] [16] Recently, Vesole et al 17 showed also that in refractory patients, high-dose melphalan followed by autologous stem cell transplantation was feasible and probably resulted in improved survival.
To improve results, tandem transplantations have been introduced. 6, 7, 18 This approach generally makes use of stem cells harvested before the first transplant. A preliminary analysis of a study comparing single and double transplants, shows some benefit of double transplants. 19 Since almost all grafts harvested before going to single or double transplants contain monoclonal myeloma precursor B cells, it could be an advantage to develop a strategy including a second stem cell harvest after the first transplant to be reinfused after the second high-dose chemotherapy, in order to minimise myeloma cell contamination of the graft. 20 We report on the results of such a strategy, both in untreated and pre-treated patients. In our double transplant approach, we utilised the G-CSF-stimulated whole blood transplant procedure for rescue after the first, high-dose melphalan containing chemotherapy, a technique we introduced in 1996. 11 This type of stem cell harvest contains a rather low number of CD34 ϩ cells. However, these cells are of a better quality than CD34 ϩ cells in leucapheresis transplants. Recently, we showed that vitality of CD34 ϩ cells in whole blood is Ͼ90% as compared with Ͼ60% early apoptotic and dead CD34 ϩ cells in frozen and subsequently thawed leucapheresis transplants. 21 Nevertheless, the number of slowly recovering patients leaves room for improving the mobilisation procedure.
Subsequently, we tried to harvest stem cells. In the first 11 patients bone marrow stem cells were harvested. This approach proved feasible but regularly required large volume harvests with only marginal CD34 ϩ cell counts. Further patients were mobilised with G-CSF only. Of the 55 patients in whom mobilisation was attempted, a satisfactory number of peripheral CD34 ϩ cells was harvested in 45. However, the number of leucaphereses needed was high, and in some patients more than one mobilisation period was needed resulting in 13 leucapheresis procedures in one patient.
Reasons for the insufficient harvest after mobilisation were apparent in most patients. Eight of these 10 patients were pre-treated with more than one M/P course (range 1-28). At the start of mobilisation these patients had low platelet counts and during leucaphereses the number of platelets declined fast. Most of these 10 patients ended up with platelet counts Ͻ50 ϫ 10 9 /l after the procedure; four patients developed platelet counts Ͻ20 ϫ 10 9 /l. This was not seen in upfront treated patients. In four of the 10 patients progression was assessed just after or at the time of mobilisation.
Of the 90 patients entering the protocol and receiving HDM, only 49 proceeded to the second transplant. The most frequent reasons for not reaching the second transplant were inadequate recovery after HDM (14) , progressive disease before (4) or after (3) the second harvest, inadequate mobilisation (7) and death before Bu/Cy (5). Of the 41 patients, who failed to proceed to Bu/Cy, 27 patients showed a response after HDM.
The only statistically significant difference between those patients who proceed to Bu/Cy as compared with those who failed, was their being treated upfront as opposed to after failing initial therapy, which consisted almost always of melphalan-containing regimens. Relapse after or resistance to oral melphalan apparently translated into poor response to or poor mobilisation after HDM, a finding that is not unexpected. Especially, there was no relationship between the numbers of CD34 ϩ cells in the whole blood harvest as compared with the numbers in the second harvest after HDM.
It appears that the rather low percentage of patients proceeding through the second transplant (54%) is explained by the high number of pre-treated patients. Of the patients not pre-treated, 70% completed the protocol, a number approaching that in the double transplantation protocol of Attal et al. 19 Although it is not very appropriate to dwell on survival results in a pilot study aiming at feasibility, the data are promising. The patients who only received HDM and who were more extensively pre-treated, experienced a median survival of 26 months, but those who proceeded to the second transplant, and were mostly treated upfront, had a median survival of 61 months. Considering that these survival data are taken from HDM, these data compare well with those of the Attal study. 5 It is most probable that better mobilisation procedures would increase the number of patients completing the whole protocol by improving the recovery rate after HDM and increasing the number of patients that could successfully be mobilised after HDM. The combination of G-CSF and stem cell factor seems promising in this respect 22 and we are currently performing a pilot study, which incorporates this combination in the double transplant protocol. After optimalisation of our protocol, it remains to be proven that the number of contaminating tumour cells is lower in the second harvest, and that double transplants improve patient outcome.
